CARLSBAD, Calif.--(BUSINESS WIRE)--The University of Cambridge and Life Technologies Corporation (NASDAQ:LIFE), announced today the formation of a collaboration to advance translational research studies in key disease areas such as cancer, diabetes and neurological disorders. Through this collaboration, next generation sequencing technology will be made available to the European research and clinical communities through the Eastern Sequence and Informatics Hub at Addenbrooke’s Hospital in Cambridge.
